An interventional study of Placebo and A+HA premium oral hyaluronic acid drink in Knee Pain Chronic, sponsored by Taipei Medical University. Not yet recruiting at 1 site in Taiwan. Open to participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-02.
Sponsored by Taipei Medical University · Not applicable, Interventional, and Treatment
Among 23 studies in Chronic Pain with a site in Taiwan — 3 open to participants now, 4 under way, none of them phase 3. Chronic Pain · Taiwan.
Among the 23 studies in Chronic Pain with a site in Taiwan, this one is the 12th largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2026, is one of 14 with no phase, and was the 23rd registered.
3,227 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.
Browse Chronic Pain studies →3 of the 23 studies in Chronic Pain with a site in Taiwan are open now. Recruiting first, the newest first:
Shin Kong Wu Ho-Su Memorial Hospital · Sites in Taiwan
Ages 18–80
Taipei Medical University Hospital · Sites in Taiwan
Ages 20+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 45 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 3 · Phase 4 1
First in 2010; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 60 across 2,387 interventional studies indexed under Chronic Pain.
Median enrollment 67 across the 20 interventional studies, 42 across the 3 observational. Of the 12 that completed or were terminated, 3 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 23 have an industry lead sponsor. The 10 most frequent:
Taipei Medical University is the lead sponsor of 257 studies on the registry; 59 are open to participants now.
Taipei Medical University has 1 study filed under Chronic Pain — fewer than ten, so there is no comparison to draw.
1 of the studies in Chronic Pain with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07800676Taipei Medical UniversityA+HA Premium Oral Hyaluronic Acid Drink Functional Evaluation Trial for Delaying Joint Pain | 2027-01-31 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies in Chronic Pain with a site in Taiwan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Evaluate the effect of A+HA premium oral hyaluronic acid drink on relieving knee pain.
Arthritis is an inflammation of one or more joints that is characterized by pain, stiffness (especially in the early morning or after exercise), swelling, deformation, and/or reduced mobility. Osteoarthritis, also known as degenerative arthritis, is caused by abnormal damage to the cartilage at the ends of bones. Some patients are caused by injury or congenital abnormalities in the proteins that make up cartilage.
Once the cartilage tissue changes from smooth to rough, or into small pieces. Cartilage is gradually destroyed, and the normally smooth surface becomes irregular. Osteoarthritis usually occurs in joints that require weight load, such as the spine, knees, hips and back, and is usually preceded by some pain and Symptoms of stiffness (mostly stiffness first, then pain), but swelling is not necessarily present. However, a small number of them will cause disability, but once the bones become more fragmented, they are more likely to cause fractures. When osteoarthritis is more severe, the bones can overgrow into osteophytes, known as bone spurs. When bone spurs develop, they can be detected with X-rays, usually in the neck or waist near degenerative cartilage. Formation, these phenomena will not produce any changes in appearance.
Osteoarthritis usually does not occur in adults under the age of 40. Most patients are over the age of 60. Symptoms may be so mild that you are unaware of them until detected by X-ray. The incidence is almost higher in women than in men. three times. Degenerative arthritis is increasing among the elderly in Taiwan. It has become a very important health problem and directly affects the quality of life. Pain control can improve the quality of life.
Previous studies have shown that orally administered hyaluronic acid (HA) can bind to toll-like receptor 4 (TLR-4) on intestinal epithelial cells, thereby increasing the secretion of the anti-inflammatory cytokine IL-10 and suppressor of cytokine signaling 3 (SOCS3), while suppressing the expression of the pro-inflammatory cytokine pleiotrophin, ultimately alleviating osteoarthritis. Regarding the regulation of cartilage degradation-related factors, HA can reduce irregularities on the cartilage surface as well as the loss of cartilage tissue and chondrocytes by suppressing the mRNA expression of MMP-3, MMP-9, and MMP-13 in cartilage tissue. In terms of oxidative stress, HA may also alleviate cartilage damage by downregulating inducible nitric oxide synthase (iNOS), thereby reducing nitric oxide (NO) production, and by inhibiting cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) production. To further enhance its efficacy in improving osteoarthritis, hyaluronic acid was combined with glucosamine and chondroitin. Previous studies have demonstrated that these two ingredients can improve connective tissue function and reduce cartilage matrix degradation. Therefore, the aim of this study was to investigate the effects of A+HA premium oral hyaluronic acid drink on improving knee pain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo use contents without active ingredients
Dietary Supplement: Placebo
A+HA premium oral hyaluronic acid drink contains hyaluronic acid, glucosamine hydrochloride, and chondroitin
Dietary Supplement: A+HA premium oral hyaluronic acid drink
1 drink daily
1 drink daily
Points change of pain evaluation scale
Self-assess pain using a visual analog scale (VAS), which is a straight line 10 cm in length, with 0 cm on the left representing no pain and 10 cm on the right representing extreme pain. Explain to the subjects that the pain intensity increases from left to right. Ask the subjects to mark the point on the line that corresponds to their pain level, and then record the distance in centimeters from the 0 cm mark. Record the points that the subjects wrote.
Time frame: From the start to the end of treatment at 12 weeks
Points change of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), a widely used questionnaires used by health professionals to evaluate the condition of patients with osteoarthritis of the knee and hip, and the total score was 96 points (Minimum: 0 points; Maximum: 96 points). The question content was divided into three parts: Pain (20 points), Stiffness (8 points), and Physical function (68 points). The higher score meant worse knee joint function. Record the points that the subjects got.
Time frame: From the start to the end of treatment at 12 weeks
Concentration change of aspartate aminotransferase (AST)
Measured from participants' blood samples for safety monitoring purposes
Time frame: From the start to the end of treatment at 12 weeks
Concentration change of alanine aminotransferase (ALT)
Measured from participants' blood samples for safety monitoring purposes
Time frame: From the start to the end of treatment at 12 weeks
Concentration change of blood glucose
Measured from participants' blood samples for safety monitoring purposes
Time frame: From the start to the end of treatment at 12 weeks
Concentration change of high-density lipoprotein
Measured from participants' blood samples for safety monitoring purposes
Time frame: From the start to the end of treatment at 12 weeks
Concentration change of low-density lipoprotein
Measured from participants' blood samples for safety monitoring purposes
Time frame: From the start to the end of treatment at 12 weeks
Concentration change of free fatty acid
Measured from participants' blood samples for safety monitoring purposes
Time frame: From the start to the end of treatment at 12 weeks
Concentration change of cholesterol
Measured from participants' blood samples for safety monitoring purposes
Time frame: From the start to the end of the treatment at 12 weeks
Concentration change of triglyceride
Measured from participants' blood samples for safety monitoring purposes
Time frame: From the start to the end of treatment at 12 weeks
Count change of differential count (DC)
Measured from participants' blood samples for safety monitoring purposes
Time frame: From the start to the end of treatment at 12 weeks
Mean corpuscular volume (MCV)
Measured from participants' blood samples for safety monitoring purposes
Time frame: From the start to the end of treatment at 12 weeks
Concentration change of hemoglobin
Measured from participants' blood samples for safety monitoring purposes
Time frame: From the start to the end of treatment at 12 weeks
Concentration change of hematocrit
Measured from participants' blood samples for safety monitoring purposes
Time frame: From the start to the end of treatment at 12 weeks
Red blood cell count
Measured from participants' blood samples for safety monitoring purposes
Time frame: From the start to the end of treatment at 12 weeks
Concentration change of gamma-glutamyl transferase （γ-GT）
Measured from participants' blood samples for safety monitoring purposes
Time frame: From the start to the end of treatment at 12 weeks
Concentration change of albumin
Measured from participants' blood samples for safety monitoring purposes
Time frame: From the start to the end of treatment at 12 weeks
Concentration change of blood urea nitrogen (BUN)
Measured from participants' blood samples for safety monitoring purposes
Time frame: From the start to the end of treatment at 12 weeks
Concentration change of creatinine
Measured from participants' blood samples for safety monitoring purposes
Time frame: From the start to the end of treatment at 12 weeks
Concentration change of urea acid
Measured from participants' blood samples for safety monitoring purposes
Time frame: From the start to the end of treatment at 12 weeks
Concentration change of thyroid-stimulating hormone (TSH)
Measured from participants' blood samples for safety monitoring purposes
Time frame: From the start to the end of treatment at 12 weeks
Concentration change of triiodothyronine (T3)
Measured from participants' blood samples for safety monitoring purposes
Time frame: From the start to the end of treatment at 12 weeks
Concentration change of thyroxine (T4)
Measured from participants' blood samples for safety monitoring purposes
Time frame: From the start to the end of treatment at 12 weeks
Concentration change of sodium (Na)
Measured from participants' blood samples for safety monitoring purposes
Time frame: From the start to the end of treatment at 12 weeks
Concentration change of potassium (K)
Measured from participants' blood samples for safety monitoring purposes
Time frame: From the start to the end of treatment at 12 weeks
Concentration change of calcium (Ca)
Measured from participants' blood samples for safety monitoring purposes
Time frame: From the start to the end of treatment at 12 weeks
Concentration change of magnesium (Mg)
Measured from participants' blood samples for safety monitoring purposes
Time frame: From the start to the end of treatment at 12 weeks
Concentration change of phosphorus (P)
Measured from participants' blood samples for safety monitoring purposes
Time frame: From the start to the end of treatment at 12 weeks
Change of urine pH value
Measured from participants' blood samples for safety monitoring purposes
Time frame: From the start to the end of treatment at 12 weeks
Concentration change of urine protein
Measured from participants' blood samples for safety monitoring purposes
Time frame: From the start to the end of treatment at 12 weeks
Concentration change of urine glucose
Measured from participants' blood samples for safety monitoring purposes
Time frame: From the start to the end of treatment at 12 weeks
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Jan 2027, 4 months later.
Of 1,295 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 4 months is below that.
Counting every sponsor, half of 1,378 studies reached it within 20 months; a quarter within 9 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.